Navigation Links
IASP declares the Global Year Against Pain in Women
Date:10/16/2007

Seattle, WA October 15, 2007 Today, the International Association for the Study of Pain (IASP) has declared 2008 the Global Year Against Pain in Women to draw attention to the significant impact of chronic pain on women and the need for more effective care. Lack of awareness of pain issues affecting women and gender disparities in treatment and research contribute to the suffering of millions of women.

Chronic pain affects a higher proportion of women than men, but unfortunately they are also less likely to receive treatment compared to men due to various cultural, economic and political barriers, said Troels S. Jensen, MD, President of IASP, Professor of Experimental and Clinical Pain Research, University of Aarhus, Aarhus, Denmark. IASP hopes to provide a voice to these women by drawing attention to this global issue as a first step towards reducing pain and suffering of women around the world.

Real Women, Real Pain

Research has shown that women generally experience more recurrent pain, more severe pain and longer lasting pain than men. Chronic pain conditions which affect women more than men include fibromyalgia, irritable bowel syndrome (IBS), rheumatoid arthritis, osteoarthritis, chronic pelvic pain, temporomandibular joint disorder (i.e., TMJ) and migraine headache.

Women appear to experience pain differently than men, although the reason is not entirely understood. It is believed that this difference is due to numerous biological reasons including genetic, hormonal and pharmacological factors/influences. In addition, psychosocial and cultural disease factors/influences play an important role in how women experience pain.

Taking Action

Over the next year, the Real Women, Real Pain campaign will educate the public, healthcare providers and government leaders/agencies about the lack of diagnosis and adequate treatment of chronic pain in women. This will help to:

  • Increas
    '/>"/>

Contact: Sejal Sedani
sejal.sedani@resolutecommunications.com
44-207-397-7474
WeissComm Partners
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. WHO Declares Vietnam First Country to Control SARS
2. Prime Minister Declares War on AIDS
3. WHO declares Tuberculosis – ‘An Emergency’ in Afrca
4. Iranian Government Declares Holiday Due To Pollution
5. Florida State University declares a breathtaking study which might solve the Hepatitis C Virus maze and find a cure!
6. Fao Declares Humans Spread Avian Influenza Virus
7. Myanmar Declares Herself As A Country Free of Bird flu
8. Ramadoss Declares India Yaws Free
9. China Declares War on Unsafe Foods for Soldiers
10. Skin Cancer Research To Go Global
11. Dementia - a global problem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... HR Consulting firm CPEhr, and Junior Achi...hadow Day for 30 high-students from Downtown Busin...cs such as labor law, interviewing techniques and ...f. (PRWEB) July 24, 2008 -- Los Angeles HR Consul...ofit organization, hosted a Job Shadow Day for 30 ...
(Date:7/24/2008)... As America's baby boomers age, more ...s such as diabetes that necessitate the use of med...celet jewelry gives a generation attractive incent...n. , (PRWEB) July 24, 200...g health conditions can make a statement in more w...
(Date:7/23/2008)... N.Y., July 24 /PRNewswire/ -- MediVoice(R), LLC, ... for e-Health and,e-Prescribing, has formed a stra...ovider of interactive, web-based, patient-centered...on systems to integrate and market its,mobile voic...Care(TM),(VTOC) system., "MediVoice is pleased to...
(Date:7/23/2008)...roblem For 10+ Years Even Though Some Kilns Emit M...ement Kilns in AL, CA, IA,IL, MD, MI, MT, NY, OR,...e-USNewswire/ -- For more than a decade,after Cong...rom cement,kilns across the nation, the U.S. Envir...ction. Now, a new study from Earthjustice and the,...
Breaking Medicine News(10 mins):Health News:CPEhr and Junior Achievement Prepare High-School Students For the Workforce 2Health News:CPEhr and Junior Achievement Prepare High-School Students For the Workforce 3Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 2Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 3Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 2Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 3Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 2Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 3Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 4Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 5Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 6Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 7
...r researchers have developed a new strain of mice ... certain gene contributes to a particularly deadly...of the strain by its developers at the Ohio State ... (OSUCCC) suggests that the genetic change comes e...
... blame yourself, if your taste buds get tickled at...re mention! A recent investigation into the reaso...arian food has shown that such tendencies are gene...rs opine that, this could be the only way, the bod...
...umber of cases of kidney cancer has been rising ov... University of Michigan Comprehensive Cancer Cente...the detection of small, presumably curable, kidney... been paralleled by greater use of surgery for kid...
...very diabetic person in Mumbai, there is one with ...in the disease with sugar levels higher than norma...umbaikars, which is also the incidence for pre-dia... Shashank Joshi. The occurrence of diabetes is goi...
Other Medicine News:Health News:Mouse Gene With Gene Stutter Will Help Leukemia Research 2Health News:Mouse Gene With Gene Stutter Will Help Leukemia Research 3Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 3
(Date:7/23/2008)...swire-FirstCall/ -- Dendreon Corporation,(Nasdaq: ...ndent Data,Monitoring Committee (IDMC) to review i...vival relating to the Company,s Phase 3 IMPACT (IM... also known as D9902B) clinical trial,of PROVENGE(...tigational,active cellular immunotherapy for the t...
(Date:7/22/2008)...RNewswire/ -- Nonin Medical, a leading innovator,o... 20 years, has entered,the clinical testing phase ...al oxygen saturation. Today,s most common applicat...ng of the regional blood oxygenation,in the brain ...comes from an ongoing clinical study at the,Duke U...
(Date:7/22/2008)...dy Confirms Tyrima Exhibits Excellent Drug-Like ...sults Support Initiation of Phase II Clinical Tria...wswire/ -- CeNeRx BioPharma,Inc., a clinical stag...e,treatments for diseases of the central nervous s...andidate Tyrima(TM) into Phase II trials for the,t...
(Date:7/22/2008)...th chemotherapy and pegylated enzyme produces s...erapy alone - - Pegylated enzyme ...FirstCall/ -- Halozyme Therapeutics,Inc. (Nasdaq:...nd,commercializing products targeting the extracel...positive pre-clinical animal efficacy data,for its...
Breaking Medicine Technology:Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 4933 1Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 4933 2Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 4933 3Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients According to Ventri 1921 1Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients According to Ventri 1921 2Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 1Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 2Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 3Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 4Measurements Poor for Assessing Clinical Trials With Children 17915 1Measurements Poor for Assessing Clinical Trials With Children 17915 2
....H.--(BUSINESS WIRE)--May 24, 2007 - Bentley,Pharm...utical,company, today announced that a late breaki...pted for a poster presentation at the,American Dia...ago.,The abstract, entitled "Results of a Randomiz...y of Intranasal Insulin Spray,(Nasulin(TM)) and In...
...O, May 23, 2007 /PRNewswire-FirstCall/ -- Shire pl...of the,investigational medication guanfacine exten...), a selective,alpha-2A-adrenoceptor agonist. Thes...olled studies and two long-term phase III,open-lab...tric,Association (APA) annual meeting, demonstrate...
Other Medicine Technology:Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 2Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 3Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 4Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 5Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 6Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 7Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 8
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
Medicine Products: